BAP1 TUMOR PREDISPOSITION SYNDROME

BAP1 Tumor Predisposition Syndrome — a recently characterized high-penetrance hereditary cancer syndrome where one gene variant predisposes to four different cancers simultaneously, many of which are extremely rare in the general population.

Whole genome sequencing identifies BAP1 pathogenic variants — established on the ACMG SF v3.2 list — in a syndrome where a single genetic result triggers surveillance for uveal melanoma, mesothelioma, cutaneous melanoma, and renal cell carcinoma.

BAP1

About this condition

BAP1 Tumor Predisposition Syndrome

BAP1 tumor predisposition syndrome (BAP1-TPDS) is an autosomal dominant hereditary cancer syndrome caused by germline pathogenic variants in BAP1 (BRCA1-associated protein 1) on chromosome 3p21.1. BAP1 is a deubiquitylase with roles in chromatin remodeling, DNA damage response, and cell cycle control. Germline BAP1 pathogenic variants were systematically characterized only from 2011 onward — the syndrome is relatively newly described, meaning many affected families accumulated multiple unusual cancers for generations without a hereditary explanation. BAP1-TPDS is now recognized as a high-penetrance multi-tumor predisposition syndrome.

The spectrum of tumors in BAP1-TPDS is distinctive — carriers face substantially elevated risks for: uveal melanoma (ocular melanoma, affecting the choroid/iris/ciliary body; >50 times the population risk), malignant pleural mesothelioma (a rare cancer strongly associated with asbestos exposure, now recognized as also occurring in BAP1 carriers with minimal or no asbestos history), cutaneous melanoma (multiple primary melanomas, often with distinctive melanocytic BAP1-mutated atypical intradermal tumors — 'BAPoma' lesions), and renal cell carcinoma (particularly clear cell and chromophobe subtypes). Each of these cancers is individually uncommon; their co-occurrence in a family is the epidemiological signal that identified BAP1-TPDS.

The clinical implications of a BAP1 molecular diagnosis are immediate and multi-specialty. Annual ophthalmic examination including fundoscopic evaluation (uveal melanoma surveillance), annual dermatological examination with dermatoscopy (cutaneous melanoma and BAPoma surveillance), renal imaging beginning in the third to fourth decade (RCC surveillance), annual chest imaging consideration (mesothelioma surveillance in exposed carriers), and cascade testing of all first-degree relatives are initiated at diagnosis. Critically, BAP1-associated mesothelioma is being recognized as a distinct clinical entity from asbestos-induced mesothelioma — BAP1 mesothelioma patients tend to be younger, have longer survival post-diagnosis, and may have different chemotherapy response profiles.

Gene locus: BAP1 (3p21.1)

BAP1 was recognized as a hereditary cancer gene only after 2011 and is not included on many older hereditary cancer panels. Families with uveal melanoma, mesothelioma, or unusual cancer clustering may have BAP1-TPDS and never been appropriately tested.

BAP1 is missing from older hereditary cancer panels — families with unusual cancer histories were never tested

The systematic characterization of BAP1-TPDS began only in 2011. Many families with BAP1 pathogenic variants received hereditary cancer panels in the preceding decade that did not include BAP1. Individuals with family histories including uveal melanoma, mesothelioma, or unusual clustering of melanoma and renal cancer — the cardinal BAP1 tumor spectrum — may have received negative panel results from pre-2011 testing or from panels that never added BAP1 to their gene list. Whole genome sequencing evaluates the entire genome and identifies BAP1 pathogenic variants regardless of when the sequencing was performed, with no limitation of a pre-defined gene list.

A confirmed BAP1 result triggers four simultaneous cancer surveillance protocols

Unlike hereditary cancer syndromes where a single gene primarily predisposes to one cancer type, BAP1-TPDS requires coordinating surveillance across four distinct cancer types — uveal melanoma (ophthalmology), cutaneous melanoma (dermatology), renal cell carcinoma (urology/radiology), and mesothelioma (pulmonology/oncology). This multi-specialty coordination begins at first molecular diagnosis and continues annually for life. Each surveillance modality addresses a cancer that standard population screening does not include — no existing general cancer screening program covers uveal melanoma, and mesothelioma screening is not standard in undiagnosed BAP1 carriers. A molecular diagnosis is the prerequisite for activating this multi-organ surveillance network.

BAP1 Tumor Predisposition Syndrome — a recently characterized high-penetrance hereditary cancer syndrome where one gene variant predisposes to four different cancers simultaneously, many of which are extremely rare in the general population.

BAP1 Tumor Predisposition Syndrome

BAP1 was recognized as a hereditary cancer gene only after 2011 and is not included on many older hereditary cancer panels. Families with uveal melanoma, mesothelioma, or unusual cancer clustering may have BAP1-TPDS and never been appropriately tested.

BAP1 is missing from older hereditary cancer panels — families with unusual cancer histories were never tested

A confirmed BAP1 result triggers four simultaneous cancer surveillance protocols

Others in Hereditary Cancer

One test. A lifetime of answers.